Companies Assembly Biosciences
Assembly Biosciences (ASMB): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Assembly Biosciences’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers53rd pct.Of 18 peer CEOs
CEO pay, last three years
- $1,373,710FY2023
- $1,767,191FY2024
- $2,482,987FY2025
CEO total pay was $2,482,987 in fiscal 2025, up from $1,767,191 in fiscal 2024.
FY2025: salary $647,500 · bonus $0 · stock awards $661,671 · option awards $573,574
Executives and directors
Anuj Gaggar · Chief Medical OfficerJason Okazaki · CEOWilliam Delaney · Chief Scientific OfficerAnthony E. Altig · Independent DirectorGina Consylman · Independent DirectorJohn G. McHutchison, A.O., M.D · Independent DirectorLisa R. Johnson-Pratt, M.D · Independent DirectorRobert D. Cook II · DirectorSir Michael Houghton, Ph.D · Independent DirectorSusan Mahony, Ph.D · Independent DirectorTomas Cihlar, Ph.D · DirectorWilliam R. Ringo, Jr · Chair of the Board
Frequently asked questions
Who was the highest-paid executive at Assembly Biosciences in fiscal 2025?
As disclosed, Jason Okazaki (Chief Executive Officer and President) was the highest-paid executive at Assembly Biosciences in fiscal 2025, with total compensation of $2,482,987.
How does Assembly Biosciences's chief executive pay compare to its disclosed peer group?
As disclosed, Jason Okazaki's total compensation ranked at the 53rd percentile of Assembly Biosciences's disclosed peer group.
How did shareholders vote on Assembly Biosciences's executive compensation?
As disclosed, 99.95% of shareholders supported Assembly Biosciences's executive compensation in the latest say-on-pay vote.
How much does Assembly Biosciences spend in total on board compensation for fiscal 2025?
As disclosed, Assembly Biosciences reported total board compensation of $470,000 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Jason Okazaki | $647,500 | $0 | $661,671 | $573,574 | $585,000 | $0 | $15,242 | $2,482,987 |
| Chief Executive Officer and President | ||||||||
| William Delaney | 511,325 | 0 | 236,274 | 199,263 | 302,800 | 0 | 15,242 | 1,264,904 |
| Chief Scientific Officer | ||||||||
| Anuj Gaggar | 502,863 | 0 | 236,274 | 189,104 | 303,000 | 0 | 14,810 | 1,246,051 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Jason Okazaki | $2,482,987 | $1,767,191 | $1,373,710 | ↑ +715,796 |
| William Delaney | 1,264,904 | 963,467 | 811,821 | ↑ +301,437 |
| Anuj Gaggar | 1,246,051 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our Compensation Philosophy is to Provide Competitive Overall Compensation That Attracts, Retains and Motivates Superior Performers.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards, LLC |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Jason Okazaki | RSU | — | — | — | 38,380 | — | $661,671 |
| Anuj Gaggar | RSU | — | — | — | 13,705 | — | 236,274 |
| William Delaney | RSU | — | — | — | 25,500 | — | 199,263 |
| William Delaney | RSU | — | — | — | 13,705 | — | 236,274 |
| Jason Okazaki | RSU | — | — | — | 71,100 | — | 573,574 |
| Anuj Gaggar | RSU | — | — | — | 24,200 | — | 189,104 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Jason Okazaki | $1,235,245 | $0 | $0 | 0.0% |
| Anuj Gaggar | 425,378 | 0 | 0 | 0.0% |
| William Delaney | 435,537 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| William Delaney | Option | 519 | 27.6 | — |
| William Delaney | RSU | 520 | — | 17,685 |
| Jason Okazaki | RSU | 651 | — | 22,141 |
| Jason Okazaki | Option | 651 | 27.6 | — |
| William Delaney | PSU | 2,083 | — | 70,843 |
| Jason Okazaki | PSU | 2,604 | — | 88,562 |
| William Delaney | Option | 2,776 | 24.12 | — |
| Jason Okazaki | Option | 3,472 | 24.12 | — |
| William Delaney | Option | 3,646 | 10.68 | — |
| William Delaney | Option | 11,250 | 13.3 | — |
| Jason Okazaki | Option | 12,239 | 10.68 | — |
| William Delaney | PSU | 13,705 | — | 466,107 |
| Anuj Gaggar | PSU | 13,705 | — | 466,107 |
| Anuj Gaggar | Option | 19,956 | 10.2 | — |
| Anuj Gaggar | Option | 24,200 | 10.62 | — |
| William Delaney | Option | 25,500 | 10.62 | — |
| Jason Okazaki | Option | 36,563 | 13.3 | — |
| Jason Okazaki | PSU | 38,380 | — | 1,305,304 |
| Jason Okazaki | Option | 71,100 | 10.62 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| William R. Ringo, JrIndependent · Board Chair · Audit · Compensation · Nominating and Governance (Chair) · Not standing for re-election | $112,500 | $0 | $39,465 | $0 | $0 | $151,965 |
| Anthony E. AltigIndependent · Audit (Chair) · Nominating and Governance | 70,000 | 0 | 39,465 | 0 | 0 | 109,465 |
| Susan Mahony, Ph.DIndependent · Compensation (Chair) · Science and Technology | 65,000 | 0 | 39,465 | 0 | 0 | 104,465 |
| Gina ConsylmanIndependent · Audit · Compensation | 62,500 | 0 | 39,465 | 0 | 0 | 101,965 |
| John G. McHutchison, A.O., M.DIndependent · Nominating and Governance · Science and Technology | 55,000 | 0 | 39,465 | 0 | 0 | 94,465 |
| Lisa R. Johnson-Pratt, M.DIndependent · Nominating and Governance · Science and Technology | 55,000 | 0 | 39,465 | 0 | 0 | 94,465 |
| Sir Michael Houghton, Ph.DIndependent · Science and Technology | 50,000 | 0 | 39,465 | 0 | 0 | 89,465 |
| Jason A. OkazakiEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Tomas Cihlar, Ph.DNot independent | 0 | 0 | 0 | 0 | 0 | 0 |
| Robert D. Cook IINot independent | 0 | 0 | 0 | 0 | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $39,465 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | Due to the number of our newly hired senior leadership team members, the Compensation Committee expects to review its position regarding stock ownership guidelines over the next 12 months. |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $470,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $470,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Assembly Biosciences as a peer
Companies that benchmark against ASMB
4 companies name ASMB as a compensation peer
The list of companies that name ASMB as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ENTA Enanta Pharmaceuticals, Inc.ABUS Arbutus Biopharma CorporationHOOK Hookipa Pharma Inc.ADVM Adverum Biotechnologies, Inc.ALGS Aligos Therapeutics, Inc.ANTX AN2 Therapeutics, Inc.AVIR Atea Pharmaceuticals, Inc.ATYR aTyr Pharma, Inc.BDTX Black Diamond Therapeutics, Inc.CRBU Caribou Biosciences, Inc.CTMX CytomX Therapeutics, Inc.GOSS Gossamer Bio, Inc.IVVD Invivyd, Inc. Kronos Bio, Inc.DTIL Precision Biosciences, Inc.SPRO Spero Therapeutics, Inc.TERN Terns Pharmaceuticals, Inc.VXRT Vaxart, Inc.
Peer reciprocity
The companies Assembly Biosciences names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Terns Pharmaceuticals, Inc. | 2024 | Amy Burroughs | $563,701 | $807,750 | $6,476,968 | $375,000 | $8,240,502 |
| 2 | CytomX Therapeutics, Inc. | 2025 | Sean McCarthy | 675,290 | 1,150,463 | 2,158,170 | 749,572 | 4,738,495 |
| 3 | Adverum Biotechnologies, Inc. | 2024 | Laurent Fischer | 691,795 | 171,363 | 2,839,252 | 415,080 | 4,131,290 |
| 4 | Aligos Therapeutics, Inc. | 2025 | Lawrence Blatt | 651,718 | 0 | 3,014,995 | 371,479 | 4,057,234 |
| 5 | aTyr Pharma, Inc. | 2025 | Sanjay Shukla | 638,977 | 0 | 2,595,200 | 210,862 | 3,456,253 |
| 6 | Atea Pharmaceuticals, Inc. | 2025 | Jean-Pierre Sommadossi | 703,490 | 1,315,800 | 962,368 | 422,094 | 3,403,752 |
| 7 | Enanta Pharmaceuticals, Inc. | 2025 | Jay Luly | 803,300 | 128,550 | 1,223,975 | 591,665 | 2,769,548 |
| 8 | Assembly Biosciences | 2025 | Jason Okazaki | 647,500 | 661,671 | 573,574 | 585,000 | 2,482,987 |
| 9 | Gossamer Bio, Inc. | 2025 | Faheem Hasnain | 649,649 | 0 | 1,392,006 | 254,800 | 2,300,455 |
| 10 | Black Diamond Therapeutics, Inc. | 2025 | Mark Velleca | 667,400 | 189,000 | 1,006,030 | 348,717 | 2,234,919 |
| 11 | Precision Biosciences, Inc. | 2025 | Michael Amoroso | 650,875 | 1,025,086 | 0 | 0 | 2,189,467 |
| 12 | Invivyd, Inc. | 2025 | William Duke | 485,000 | 483,000 | 905,445 | 0 | 2,141,222 |
| 13 | Spero Therapeutics, Inc. | 2025 | Esther Rajavelu | 577,179 | 413,705 | 0 | 372,000 | 2,061,496 |
| 14 | Caribou Biosciences, Inc. | 2025 | Rachel Haurwitz | 667,534 | 192,818 | 654,541 | 0 | 1,840,965 |
| 15 | AN2 Therapeutics, Inc. | 2025 | Eric Easom | 603,750 | 164,133 | 275,539 | 332,063 | 1,382,985 |
| 16 | Arbutus Biopharma Corporation | 2025 | Lindsay Androski | 437,750 | 0 | 714,751 | 216,512 | 1,369,013 |
| 17 | Hookipa Pharma Inc. | 2023 | Joern Aldag | 567,451 | 0 | 282,088 | 280,888 | 1,130,427 |
| — | Vaxart, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Assembly Biosciences | not disclosed | Options 100 | No | Alpine Rewards, LLC |
| Adverum Biotechnologies, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Aligos Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Radford |
| AN2 Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Arbutus Biopharma Corporation | 110% of target% | not disclosed | not disclosed | Radford (Aon) |
| Atea Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| aTyr Pharma, Inc. | 60% (Committee lowered payout from 75% achievement to 60% given EFZO-FIT study results)% | Option 100 | not disclosed | Radford (part of the Rewards Solutions practice at Aon plc) |
| Black Diamond Therapeutics, Inc. | 95% | not disclosed | not disclosed | Aon Human Capital Solutions (Aon plc) |
| Caribou Biosciences, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| CytomX Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Enanta Pharmaceuticals, Inc. | not disclosed | Options 80 · PSU 10 · MSU 10 | No | Alpine Rewards LLC |
| Gossamer Bio, Inc. | 65% | not disclosed | No | Alpine Rewards |
| Hookipa Pharma Inc. | not disclosed | Option 100 | not disclosed | Aon Radford |
| Invivyd, Inc. | 132% | not disclosed | not disclosed | Alpine Rewards |
| Precision Biosciences, Inc. | 115% | RSU 100 | not disclosed | Aon |
| Spero Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Meridian Compensation Partners, LLC |
| Terns Pharmaceuticals, Inc. | 120% | not disclosed | No | Alpine Rewards |
| Vaxart, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-04 | 11,293,061 | 5,401 | 18,379 | 99.95% | Passed |
| 2025 | 2025-06-05 | 2,975,064 | 784,522 | 18,723 | 79.13% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-04 | 99.95%a |
| 2025 | 2025-06-05 | 79.13%b |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes are not considered votes cast and will have no effect on the vote for these proposals.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes are not considered votes cast and will have no effect on the vote for these proposals.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | Greater-than-10% holder | 2026-05-26 | A | 471,698 | $27 | $12,499,997 | Common | Form 4 ↗ |
| Michael Houghton | Director | 2026-06-04 | A | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gina Consylman | Director | 2026-06-04 | A | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Susan Mahony | Director | 2026-06-04 | A | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lisa Johnson-Pratt | Director | 2026-06-04 | A | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Anthony E. Altig | Director | 2026-06-04 | A | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John G. McHutchison | Director | 2026-06-04 | A | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeanette M. Bjorkquist | PFO and PAO | 2026-06-17 | D | 29 | 23 | 674 | Common | Form 4 ↗ |
| Anuj Gaggar | Chief Medical Officer | 2026-10-30 | A | 13,705 | 0 | 0 | Common | Form 4 ↗ |
| William Delaney | Chief Scientific Officer | 2026-10-30 | A | 13,705 | 0 | 0 | Common | Form 4 ↗ |
| Jason A. Okazaki | Director | 2026-10-30 | A | 38,380 | 0 | 0 | Common | Form 4 ↗ |
| Jeanette M. Bjorkquist | PFO and PAO | 2026-10-30 | A | 3,840 | 0 | 0 | Common | Form 4 ↗ |
| Nicole S. White | Chief Manufacturing Officer | 2026-10-30 | A | 13,705 | 0 | 0 | Common | Form 4 ↗ |
| Jeanette M. Bjorkquist | PFO and PAO | 2026-11-02 | D | 9 | 20 | 183 | Common | Form 4 ↗ |
| Jeanette M. Bjorkquist | PFO and PAO | 2026-11-02 | D | 718 | 20 | 14,078 | Common | Form 4 ↗ |
| Nicole S. White | Chief Manufacturing Officer | 2026-11-02 | D | 29 | 20 | 590 | Common | Form 4 ↗ |
| Nicole S. White | Chief Manufacturing Officer | 2026-11-02 | D | 2,564 | 20 | 50,274 | Common | Form 4 ↗ |
| Anuj Gaggar | Chief Medical Officer | 2026-11-02 | D | 29 | 20 | 590 | Common | Form 4 ↗ |
| Anuj Gaggar | Chief Medical Officer | 2026-11-02 | D | 2,564 | 20 | 50,274 | Common | Form 4 ↗ |
| Jason A. Okazaki | Director | 2026-11-02 | D | 69 | 20 | 1,404 | Common | Form 4 ↗ |
| Jason A. Okazaki | Director | 2026-11-02 | D | 6,133 | 20 | 120,254 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (65 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Jason Okazaki. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · page 54. As printed: 2,482,987. View filing ↗
- Section 01, William Delaney. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · page 54. As printed: 1,264,904. View filing ↗
- Section 01, Anuj Gaggar. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · page 54. As printed: 1,246,051. View filing ↗
- Section 03, Jason Okazaki RSU. DEF 14A, filed 2026-04-22. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Anuj Gaggar RSU. DEF 14A, filed 2026-04-22. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, William Delaney RSU. DEF 14A, filed 2026-04-22. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, William Delaney RSU. DEF 14A, filed 2026-04-22. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Jason Okazaki RSU. DEF 14A, filed 2026-04-22. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Anuj Gaggar RSU. DEF 14A, filed 2026-04-22. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-19. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, William R. Ringo, Jr. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 151,965. View filing ↗
- Section 08, Anthony E. Altig. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 109,465. View filing ↗
- Section 08, Susan Mahony, Ph.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 104,465. View filing ↗
- Section 08, Gina Consylman. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 101,965. View filing ↗
- Section 08, John G. McHutchison, A.O., M.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 94,465. View filing ↗
- Section 08, Lisa R. Johnson-Pratt, M.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 94,465. View filing ↗
- Section 08, Sir Michael Houghton, Ph.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 89,465. View filing ↗
- Section 08, Jason A. Okazaki. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Tomas Cihlar, Ph.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Robert D. Cook II. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, GILEAD SCIENCES, INC. 2026-05-26. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Houghton 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gina Consylman 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susan Mahony 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lisa Johnson-Pratt 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anthony E. Altig 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John G. McHutchison 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeanette M. Bjorkquist 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anuj Gaggar 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Delaney 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason A. Okazaki 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeanette M. Bjorkquist 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nicole S. White 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeanette M. Bjorkquist 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeanette M. Bjorkquist 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nicole S. White 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nicole S. White 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anuj Gaggar 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anuj Gaggar 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason A. Okazaki 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason A. Okazaki 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-05. Item 5.07 · say-on-pay result. As reported: 99.95% (votes for as printed: 11,293,061). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-09. Item 5.07 · say-on-pay result. As reported: 79.13% (votes for as printed: 2,975,064). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 470,000 + equity 0 + all other 0 = 470,000, summed across the director compensation table rows.
- Terns Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Terns Pharmaceuticals, Inc.'s own proxy. As printed: 8,240,502. View filing ↗
- CytomX Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in CytomX Therapeutics, Inc.'s own proxy. As printed: 4,738,495. View filing ↗
- Adverum Biotechnologies, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Adverum Biotechnologies, Inc.'s own proxy. As printed: 4,131,290. View filing ↗
- Aligos Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Aligos Therapeutics, Inc.'s own proxy. As printed: 4,057,234. View filing ↗
- aTyr Pharma, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-26. CEO total compensation as printed in aTyr Pharma, Inc.'s own proxy. As printed: 3,456,253. View filing ↗
- Atea Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Atea Pharmaceuticals, Inc.'s own proxy. As printed: 3,403,752. View filing ↗
- Enanta Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-01-26. CEO total compensation as printed in Enanta Pharmaceuticals, Inc.'s own proxy. As printed: 2,769,548. View filing ↗
- Assembly Biosciences (subject), Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Assembly Biosciences's own proxy. As printed: 2,482,987. View filing ↗
- Gossamer Bio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Gossamer Bio, Inc.'s own proxy. As printed: 2,300,455. View filing ↗
- Black Diamond Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Black Diamond Therapeutics, Inc.'s own proxy. As printed: 2,234,919. View filing ↗
- Precision Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Precision Biosciences, Inc.'s own proxy. As printed: 2,189,467. View filing ↗
- Invivyd, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Invivyd, Inc.'s own proxy. As printed: 2,141,222. View filing ↗
- Spero Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Spero Therapeutics, Inc.'s own proxy. As printed: 2,061,496. View filing ↗
- Caribou Biosciences, Inc., Section 10b CEO total. DEFR 14A, filed 2026-05-01. CEO total compensation as printed in Caribou Biosciences, Inc.'s own proxy. As printed: 1,840,965. View filing ↗
- AN2 Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in AN2 Therapeutics, Inc.'s own proxy. As printed: 1,382,985. View filing ↗
- Arbutus Biopharma Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-14. CEO total compensation as printed in Arbutus Biopharma Corporation's own proxy. As printed: 1,369,013. View filing ↗
- Hookipa Pharma Inc., Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in Hookipa Pharma Inc.'s own proxy. As printed: 1,130,427. View filing ↗
- Section 10a, Adverum Biotechnologies, Inc. reciprocity. DEF 14A. Adverum Biotechnologies, Inc. names Assembly Biosciences in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Atea Pharmaceuticals, Inc. reciprocity. DEF 14A. Atea Pharmaceuticals, Inc. names Assembly Biosciences in its own disclosed peer group (read from its most recent proxy). View filing ↗